SCHEMBL10113674

SCHEMBL10113674

CC(C)S(=O)(=O)NCCCCC(=O)Nc1ccc(N2CCCCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.59
NPC1 O15118 3/20 0.59
TP53 P04637 2/20 0.59
RAB9A P51151 2/20 0.59
GAA P10253 3/20 0.58
NPSR1 Q6W5P4 2/20 0.58
HSD17B10 Q99714 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 3/20 0.56
MAPT P10636 9/20 0.55
CYP2C19 P33261 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
CYP2D6 P10635 2/20 0.55
LMNA P02545 1/20 0.55
HTT P42858 1/20 0.55
CYP3A4 P08684 2/20 0.51
GFER P55789 2/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10113690 0.99 GAA (0.59) SMN1; SMN2NPC1TP53RAB9AGAA
SCHEMBL10113712 0.97 SMN1; SMN2 (0.56) SMN1; SMN2NPC1TP53RAB9AGAA
SCHEMBL10113695 0.90 MAPT (0.55) SMN1; SMN2NPC1RAB9AGAANPSR1
SCHEMBL10113693 0.90 KDM4E (0.54) SMN1; SMN2NPC1TP53RAB9AGAA
SCHEMBL10113669 0.90 ALDH1A1 (0.59) SMN1; SMN2L3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL10113698 0.90 SMN1; SMN2 (0.48) SMN1; SMN2NPC1TP53RAB9AGAA
SCHEMBL10115256 0.89 KDM4E (0.50) SMN1; SMN2NPC1TP53RAB9AGAA
SCHEMBL10115361 0.89 KDM4E (0.48) SMN1; SMN2NPC1TP53RAB9AGAA
SCHEMBL10115263 0.88 MAPT (0.54) SMN1; SMN2NPC1RAB9AGAANPSR1
SCHEMBL10113703 0.88 KDM4E (0.50) SMN1; SMN2NPC1TP53RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R SMN1; SMN2 2213/4885NPC1 1435/4885TP53 4449/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885NPC1 1353/4885TP53 4417/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885NPC1 1462/4885TP53 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.